Resistance to the mechanistic target of rapamycin (mTOR) inhibitors, which are a standard treatment for advanced clear cell renal cell carcinoma (ccRCC), eventually develops in most cases. This evidence concerns the gene MTOR and nonpapillary renal cell carcinoma.